ArticleScientific reports2025
Machine learning-based construction of a programmed cell death-related model reveals prognosis and immune infiltration in pancreatic adenocarcinoma patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The place of advanced machine learning techniques in building pancreatic adenocarcinoma survival and recurrence prognosis models.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic adenocarcinoma (PAAD) is a highly lethal malignancy with limited effective prognostic biomarkers. In this study, 1,034 samples from TCGA-PAAD, GSE62452, GSE28735, GSE183795, and ICGC cohorts were systematically integrated to identify key programmed cell death-related genes (PCDRGs) associated with patient prognosis. Differential expression analysis and Univariate Cox regression analysis identified 17 candidate PCD-related genes significantly associated with overall survival. Using a comprehensive machine learning framework involving 117 algorithmic combinations under a Leave-one-out cross-validation (LOOCV) strategy, we identified the StepCox[both] + Ridge as the best algorithms composition to construct a prognostic model based on six PCDRGs, ITGA3, CDCP1, IL1RAP, CLU, PBK, and PLAU. The model was validated to have robust predictive performance. Risk scores were significantly correlated with clinical features, immune microenvironment characteristics, and chemotherapeutic sensitivity. High-risk patients exhibited worse prognosis and immunosuppressive infiltration patterns. Furthermore, consensus clustering identified two PAAD molecular subtypes with distinct PCDRGs expression patterns and survival outcomes. A nomogram integrating risk score and clinical variables exhibited strong prognostic accuracy for 1-, 3-, and 5-year survival prediction. In summary, we established and validated a PCD-related prognostic signature that effectively stratifies PAAD patients by clinical outcome, immune contexture, and therapeutic response, providing novel insights for personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.